Skip to content

Cellulose Sulfate and HIV Transmission Among Women

Randomized Controlled Trial of 6% Cellulose Sulfate Gel and the Effect on Vaginal HIV Transmission

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00153777
Enrollment
1428
Registered
2005-09-12
Start date
2005-07-31
Completion date
2007-03-31
Last updated
2015-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infection

Keywords

HIV prevention, Randomized controlled trial, Women, Sexually transmitted infections, HIV Seronegativity

Brief summary

The purpose of the study is to determine the effect of cellulose sulfate on the transmission of HIV to women via vaginal intercourse. The secondary objectives are the effect on the transmission of gonorrhea and chlamydia via the same route. The study hypothesis is that there will be no effect.

Detailed description

Despite the availability of an effective HIV prevention method, i.e. the condom, the epidemic continues growing. There is thus an urgent need for additional HIV prevention methods. One of the possibilities is the use of microbicides, i.e. chemical products which may be used in the vagina or rectum with the potential to prevent HIV infection. Cellulose sulfate is an HIV entry inhibitor with an in vitro effect on N. gonorrhoeae (NG) and C. trachomatis (CT) and other sexually transmitted organisms. The study assess its effect on the vaginal transmission of HIV, NG and CT among women at high risk of heterosexual STI infection (defined as having had more than two partners in the last three months and an average of three sexual acts per week). The study is randomized, triple-blinded, placebo controlled.

Interventions

DRUGCellulose Sulfate gel (6%)

Sponsors

United States Agency for International Development (USAID)
CollaboratorFED
Bill and Melinda Gates Foundation
CollaboratorOTHER
CONRAD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* at least 18 years old * an average of at least three vaginal sex acts per week, at least three different partners in the last three months, expecting to continue this behavior * HIV negative * willing and able to comply with the protocol

Exclusion criteria

* pregnancy * allergy to latex or spermicides * intravenous drug user

Design outcomes

Primary

MeasureTime frame
Combined incidence of HIV-1 and HIV-2 in the study.1 year

Secondary

MeasureTime frame
Time-to-first incidental gonococcal or chlamydial infection.1 year

Countries

Benin, India, South Africa, Uganda

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 5, 2026